P53 타깃 항암제

이전 페이지 이동 다음 페이지 이동

와이즈만연구소와 ‘P53 유전자 활용
타깃 항암 치료제 기술 이전
이스라엘 예다와 R&D 합작법인 설립

바이오리더스,
와이즈만 연구소 'P53 타깃
항암제' 도입

img
  • 01

    img

    P53 유전자 활용 타깃 항암 치료제 기술
    이전 이스라엘 예다와 R&D 합작법인 설립
  • 02

    img

    Inactivation of p53 in Tumors Confers a Strong Selective Advantage in the Carcinogenic Process
    Eliminating p53 function may be a prerequisite for tumor survival 1-3
    Preclinical work has shown that the absence of p53 function is a continuous resquirement for the maintenance of established tumors
    Loss of functioning p53 promotes the oncogenic phenotype 4
    Cellular insults trigger phosphorylation of the N-terminal domain of p53 leading to conformational changes 5.6
    Prevention of p53 degradation, prolonged molecular half-life, accumulation of p53 at high levels
    Cells without normal fuctioning p53 fail to recognize and address cellular stressors/abnormalities, allowing uncontrolled replication of affected cells 4
    When p53 is functioning properly, oncogenic mutations are not propagated, as DNA repair activities are intact and cell cycling is tightly controlled 6
    1. Ventuar A, Kirs DG, McLaughlin ME, et al. Nature.
    2007; 445:661-665
    2. Martins CP, Brown-Swigart L, Evan Gl. Cell.
    2006;127:1323-1334.
    3. Xue W, Zender L, Miething C, et al. Nature.
    2001/doi:10:10.1038/nature05529.
    4.Toledo F, Wahl GM. Nature Rev Cancer.
    2006; 6:909-923
    5. Vogelstein B, Lane D, Levine AJ. Nature.
    2000;408:307-310.
    6. Nag S, Qin J, Srivenugopal KS, et al. J Biomed Res,
    2013;27:254-271
  • 03

    img

    p53 is the Most Frequently Altered Gene in Human Cancer
    Somatic mutations in p53 have been seen in several human tumors types-p53 multations or deletions are observed in apporoximately 50% of all solid tumors
    Missense multations in p53 are frequent, and can resu in gain of function changes that enhance metastatic potential and invasiveness
    In many tumor types, p53 mutations have been associated with a poorer prognosis with diminished overall survival and more aggressive tumor behavior
    p53 is not mutated in up to 50% of solid tumors and is generally not mutated in hematologic malignancies
    In these tumors, wild-type p53(p53wt) is most likely inactivated - inacyivation of p53 plays a critical role in development and progression of the cancer5
    1. Toledo F, Wahl GM. Nature Rev Cancer.
    2006; 6:909-923
    2. Eischen CM, Lozano G. Human Mutation.
    2014; 35:728-737.
    3. Ventuar A, Kirs DG, McLaughlin ME, et al. Nature.
    2007; 445:661-665
    4. VuBT, Vassilev LT. Curr Topics Micrbio Immunol.
    2011;348:151-172.
    5. Pal S, Bhattacharjee A, Ali A, et al, J Inflammation.
    2014;11023
p53 is the Most Frequently Altered Gene in Human Cancer

Somatic mutations in p53 have been seen in several human tumors types-p53 multations or deletions are observed in apporoximately 50% of all solid tumors

* Arrested cell proliferation
* Death of cancer cells
* Sensitization of refractory cancers

img